by jowen | Sep 28, 2018 | Cancer, Immunotherapy
Invest New Drugs 2017 – Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J., . . . Schneller, F., III. (2017, March 1). A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta...
by jowen | Sep 28, 2018 | Cancer, Glucans
International Journal of Clinical and Experimental Medical Sciences 2016 — Our previous work was devoted to the possibility of positively influencing some immune mechanisms in patients suffering from cancer related fatigue. The relation between cancer and fatigue is...
by jowen | Sep 28, 2018 | Cancer, Glucans
International Clinical Pathology Journal 2017 —Vetvicka, Vaclav, and Jana Vetvickova. “Β-Glucan – Is the Current Research Relevant?”. International Clinical Pathology Journal4.2 (2017): 89. This article focuses on the need for more research with Beta Glucan both on...
by jowen | Sep 28, 2018 | Cancer
Int. J. Biol. Macromol. 2007 — Article shows that Beta 1,3 Glucans, in addition to enhancing the immune system, enhances the effects of chemo-therapy drugs and prevents or reverses their negative effects on the immune system. Also, article discusses the uptake of...
by jowen | Sep 28, 2018 | Cancer, Immunity/Immune Response/Immune Response
Clin. Exp. Immunol. 1999 — Article demonstrates that beta glucan’s CR3 binding properties can be effective against cancer tumor cells that do not have CR3 receptor sites by potentiating natural killer (NK) cells to see the tumor cells as non-self. Read...
by jowen | Sep 28, 2018 | Cancer, Glucans
Cancer Transl Med 2015 — Glucans and Cancer: Historical Perspective. The fact that glucans elicit strong and positive immune responses is well‑established. Since the 1980s, we know that glucans stimulate hematopoiesis and are useful before and during radio‑and...
